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Background: Intracellular concentrations of adenosine-5’-triphosphate (ATP) are many times greater than
extracellular concentrations (1–10 mM versus 10–100 nM, respectively) and cellular release of ATP is tightly
controlled. Transient rises in extracellular ATP and its metabolite adenosine have important signaling roles; and
acting through purinergic receptors, can increase blood flow and oxygenation of tissues; and act as
neurotransmitters. Increased blood flow not only increases substrate availability but may also aid in recovery
through removal of metabolic waste products allowing muscles to accomplish more work with less fatigue. The
objective of the present study was to determine if supplemental ATP would improve muscle torque, power, work,
or fatigue during repeated bouts of high intensity resistance exercise.
Methods: Sixteen participants (8 male and 8 female; ages: 21–34 years) were enrolled in a double-blinded,
placebo-controlled study using a crossover design. The participants received either supplemental ATP (400 mg/d
divided into 2 daily doses) or placebo for 15 d. After an overnight fast, participants underwent strength and fatigue
testing, consisting of 3 sets of 50 maximal knee extensions performed on a Biodex® leg dynamometer.
Results: No differences were detected in high peak torque, power, or total work with ATP supplementation;
however, low peak torque in set 2 was significantly improved (p < 0.01). Additionally, in set 3, a trend was detected
for less torque fatigue with ATP supplementation (p < 0.10).
Conclusions: Supplementation with 400 mg ATP/d for 15 days tended to reduce muscle fatigue and improved a
participant’s ability to maintain a higher force output at the end of an exhaustive exercise bout.
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The intracellular role of ATP as the energy source for
tissues has long been recognized [1]. However, the extra-
cellular metabolic functions of ATP have only recently
been investigated, and primary to this function is the
role of ATP in signal transduction through purinergic
receptors found in most cell types [2]. Extracellular
functions of ATP include vasodilation [3] and reduced* Correspondence: Rathmacher@mti-hmb.com
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distribution, and reproduction in any mediumpain perception [4]. Additionally, ATP is often referred
to as a cotransmitter that affects local tissue changes in
neurotransmission and neuromodulation by acting upon
both peripheral and central nervous systems [5,6].
Whereas intracellular concentrations of ATP are rela-
tively high (1-10 mM), extracellular concentrations are
tightly regulated at very low levels (10-100 nM) [7,8].
When ATP is infused into the arterial blood flow of mus-
cle, the half-life has been shown to be <1 second [9] as
ATP is rapidly degraded to adenosine by several surface-
expressed and soluble enzymes of the ectonucleoside
families [10]. ATP in blood is primarily carried by erythro-
cytes [8]. Therefore, measurement of circulating freentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Rathmacher et al. Journal of the International Society of Sports Nutrition 2012, 9:48 Page 2 of 7
http://www.jissn.com/content/9/1/48plasma ATP derived from oral supplementation may not
be possible as exogenous free ATP or its metabolite ade-
nosine are quickly taken up by blood components. In rats
chronic oral administration of ATP at 5 mg/kg/day
increased portal vein ATP concentration and nucleoside
uptake by erythrocytes which resulted in an increase in
ATP synthesis in the erythrocytes [11]. Therefore, the pos-
sibility exists for oral ATP to elicit metabolic effects
despite an apparent lack of increased systemic free ATP
concentrations.
Adenosine, resulting from the degradation of ATP,
may also act as a signaling agent through purinergic
receptors [12] which are ubiquitously present in many
cell types including smooth muscle, endothelial, and
neural [2]. Adenosine may further be degraded by ade-
nosine deaminase [10]. The labile state of ATP and its
metabolite adenosine cause hyperpolarization and vaso-
dilation in the arteriolar tree resulting in increased blood
flow through the tissue, which aids in the removal of
waste products such as lactate [13]. For example, signal-
ing by both ATP and adenosine plays an important role
in increasing blood flow by causing dilation of the
microvasculature when released from erythrocytes pas-
sing through the capillaries [13,14]. Adenosine’s effect is
also mediated by increased nitric oxide and prostacyclin
levels in microvascular endothelial cells [15]. Diverting
some of the blood flow also assures the most efficient
flow of cardiac output through the exercising muscle. In
a similar manner, the release of endogenous ATP from
cardiomyocytes occurs in response to ischemia [16], thus
resulting in increased blood flow and increased oxygen
and glucose delivery to the active muscle tissue. These
observations lead to the hypothesis that dietary supple-
mentation with ATP (and/or adenosine) should be bene-
ficial to exercising muscle tissue. However, it should be
noted that it is unlikely that ATP is absorbed intact in
humans [17,18] and the effect of oral ATP on muscle
performance is likely due to the previously describedFigure 1 Timeline of experimental procedures. Each participant particip
at least one week for supplement wash out and recovery. During each tria
placebo; or (b) 15 days oral ingestion of 400 mg ATP/d with the dosage di
the evening.purinergic signaling [2] or through ATP metabolites
such as adenosine [12,19].
Supporting this hypothesis of purinergic signaling,
Calbet et al. demonstrated that infusion of ATP at near-
maximal exercise resulted in increased blood flow to
less-active and non-muscle tissues [20]. Improving blood
flow through less active muscle tissues could remove
waste products such as lactate. Additionally, Jordan et al.
demonstrated that orally ingested ATP may be metaboli-
cally available to tissues and may influence adenine
nucleotide metabolism during exercise [21]. The study
showed that oral supplementation with ATP (225 mg)
for 14 days resulted in increased within group set-one
repetitions and increased total lifting volume on the
bench press apparatus; however, no effect was observed
at the lower dosage of 150 mg ATP per day. The current
study was designed to test the hypothesis that supple-
mental ATP would improve performance of repeated
high intensity exercise as measured by muscle torque,
power, work and fatigue.
Methods
Sixteen volunteers (8 male and 8 female; ages: 21–34
years) were enrolled in a double-blinded, placebo-
controlled study using a crossover design. The protocol
followed during each supplementation and testing period
is shown in Figure 1. Both the placebo capsules contain-
ing rice flour and the ATP capsules containing 200 mg
of Peak ATP® were obtained from a commercial manu-
facturer (TSI (USA), Inc., Missoula, MT). The ATP sup-
plement was delivered as the disodium salt. A daily
dosage of 400 mg/d was utilized for the current study
and was chosen because the 225 mg ATP/d dosage used
by Jordan et al. failed to improve bench press strength
compared with the placebo group [21], and we reasoned
that a higher dosage may be necessary to demonstrate
an effect of oral ATP on knee extension fatigue and
strength. A washout period of at least 1 week separatedated in two experimental trials, one for each treatment, separated by
l participants were assigned to either: (a) 15 days oral ingestion of
vided into two equal dosages, one in the morning and the other in
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pants consumed their assigned capsules for 15 days as
previously described. After the supplementation period,
the participants reported to the laboratory for testing
after an overnight fast of 12 h. The participants were
given a supply of capsules (each containing 200 mg per
capsule) and instructed to take two capsules each day
(total dose = 400 mg/day), one in the morning before
breakfast and one in the evening before dinner.
All of the participants were classified as healthy and
were not currently taking prescription medications or
other dietary supplements. Multi-vitamins not exceeding
the RDA were allowed. None of the participants were
classified as competitive athletes or currently partici-
pated in daily heavy physical work or weight training.
Participants had to be able to perform the fatigue testing
and also were required to commit to maintaining their
current activity levels throughout the study. Participants
also had to agree to repeat a consistent dietary intake for
the 24-hour period before each of the testing protocols.
Participants not able to meet the inclusion criteria were
excluded from the study. All procedures involving
human participants were approved by the Iowa State
University Institutional Review Board, and written
informed consent was obtained from all participants
prior to participation.
For each of the trials, participants refrained from vig-
orous exercise for three days before reporting to the
laboratory in the morning after an overnight fast
(Figure 1). Exercise consisting of light stretching and/or
mild aerobic exercise lasting less than 45 minutes was
allowed during this pre-study period. At this time, a blood
sample was obtained. Weight and height were measured
and BMI was calculated. Additionally, for characteristic
purposes only, body composition was measured using
air displacement plethysmography (BodPod®, Life Mea-
surements, Concord, CA). The participants were then
given their first week supply of blinded capsules with
instructions on proper dose scheduling and completion
of a dose-log. Participants returned to the laboratory
after the first week to receive their second week of cap-
sules and to confirm their compliance with the dosing
schedule; there were no training or nutrition journals
recorded.
At the end of the 15 days of dosing, the participants
returned to the laboratory for post-supplementation test-
ing. Another blood sample was taken and the partici-
pant’s body weight was again measured and BMI
calculated. The participants were allowed to recover
from the blood sampling for at least 30 min and then
the strength/fatigue testing measurements were taken.
No supplement was given before testing and all testing
was conducted after an overnight fast and after three
days of exercise restriction as in the preliminary testing.At the completion of each supplementation period, the
strength/fatigue testing was performed which consisted
of three 50-contraction knee extension fatigue tests con-
ducted on a Biodex® leg dynamometer (BIODEX® Multi-
Joint Systems 2: Biodex Medical version 4.5 software)
with 2 minutes of rest between the tests. During each of
the fatigue tests, the participants were instructed to
extend the knee with maximum effort at a speed of 120
degrees per second. Peak torque of each individual con-
traction was recorded. The high peak torque is the maxi-
mum force generated during each of the 50 contractions,
while the low peak torque would be the value of the low-
est peak torque produced during the last ten contractions
of each of the 50 contraction fatigue test. Work performed
and average power in the 50 contractions were also mea-
sured. Percent fatigue was calculated as the percentage
decline in high peak to low peak torque, and percent work
fatigue was calculated as the percentage decrease in the
work performed from the 1st one-third to the last one-
third of the contractions of each set. After a one week
wash out and recovery period, the participants were
switched to the other treatment and the testing was
repeated (Figure 1). Blood samples were taken from a
superficial forearm vein before and after each supplemen-
tation period and sent to a commercial laboratory for
blood chemistry and complete blood count (LabCorp,
Kansas City, MO).
Statistics
A cross-over, repeated measures ANOVA model was
used to analyze the data using the General Linear
Models (GLM) procedure in SAS (SAS Institute, Cary,
NC). No priori power analysis was performed, but the
number of participants studied was justified based upon
the Jordan et al. study [21] and the present study used
a similar number of each gender in our crossover design
as no prior art specific to exogenous ATP provided evi-
dence to warrant against the use of both men and
women. Participants were randomly assigned to treat-
ment order. Main effects of participant, order, treatment
(Trt), and Trt*time were included in the model. Least
Squares Means procedure was then used to compare
treatment means of each set. Statistical significance was
determined at p < 0.05 and trends were determined for
p > 0.05 and p < 0.10.
Results
Participant characteristics are shown in Table 1. There
were no significant changes in participant characteristics
over the two treatment periods.
High peak torque, low peak torque, and torque fatigue
of the leg muscles measured over the three exercise sets
are shown in Figure 2. No significant difference was found
for high peak torque (Figure 2A). Overall treatment main
Table 1 Participant characteristics at baseline for Placebo
and 400 mg ATP/d.*













*Studies were carried out on 16 participants (8 males and 8 females) with a
mean age of 25.3 ± 3.9 years. Data are expressed as mean ± SD.
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icance for both increased low peak torque (Figure 2B) and
decreased torque fatigue (Figure 2C). Analysis (Least
Squares Means) of the data by each set showed that ATP
supplementation significantly increased low peak torque
in set 2 (62.3 and 67.2 Nm in placebo- and ATP-
supplemented participants, respectively (p < 0.01)). Set 3
torque fatigue also tended to be less with ATP-
supplementation (60.5% and 57.8% in placebo- and
ATP-supplemented participants, respectively (p < 0.10)).
However, the improvements seen in leg low peak torque
did not lead to increased leg average power, total work, or
a decrease in work fatigue.
Blood chemistries and differential cell counts were
measured before and after each supplementation period.
While some measurement comparisons between placebo
and ATP-supplemented participants showed numerical
differences that were statistically significant, none of the
significant observations were clinically relevant and
these data showed no untoward effects of the supple-
mentation (data shown in Additional file 1: Table S1 and
Table S2).Discussion
The current study shows that 400 mg ATP per day was
effective in improving leg muscle low peak torque in set 2
(p < 0.01), and tended to decrease leg muscle fatigue in set
3 (p < 0.10) of three successive sets of knee extension exer-
cises. However, the improvement in low peak torque and
decreased fatigue were not sufficient to translate into
improvements in leg muscle power or work performed.
These observations lead us to speculate that supplemental
ATP may provide cumulative benefits in strenuous, repetitive,and exhaustive exercise activities, which could lead to
improved strength and lean body mass gains.
There is limited human data related to the potential for
oral ATP to manifest physiologic modifications that would
improve skeletal muscle efficiency or work performed [21].
As muscle undergoes prolonged work, ATP synthesis
increases in an attempt to keep up with energy demand
[22]. To accomplish this, the muscle needs substrates, such
as oxygen and glucose, supplied from the peripheral circu-
lation. Endogenous muscle stores of ATP are limited and
support maximal work for only a fraction of, or at most
1–2 seconds and is replenished by the supply of intercellu-
lar phosphocreatine for only an additional 2–7 seconds [7].
Muscle performing exhaustive exercise then relies primarily
on anaerobic glycolysis for regeneration of ATP which
results in the production of lactate and H+. The associated
decrease in intracellular pH is a factor leading to muscle
fatigue [23,24]. Therefore, during maximal exertion blood
flow is needed not only for oxygen supply to support con-
tinued oxidative phosphorylation, but also for H+ removal
for muscle pH regulation. It would seem that exogenous
ATP would likely have a greater impact on the muscles’
ability to perform fatiguing exercise by increasing substrate
availability to the muscle and/or facilitating waste product
removal through increased blood flow through the muscle
tissues.
Both ATP and adenosine can act through purinergic
receptors in endothelial smooth muscle of the vascular
system resulting in vasodilation and increased blood
flow [14,15,25]. A study by Gonzalez-Alonso showed
that intra-arterial infusion of ATP was associated with
vasodilation and increased blood flow with a significant
reduction in venous ATP levels in the non-exercising
limb suggesting utilization of ATP or metabolites [26].
These observations were confirmed by Calbet et al. who
hypothesized that increased delivery of ATP would affect
non-exercising vasoconstrictive muscle tissue [20].
These are most likely due to activation of purinergic
receptors affecting blood flow [13]. Furthermore, exo-
genous adenosine administration results in vasodilation
[14] and increased glucose and O2 uptake by muscle
which provide for an increased substrate pool [12]. The
ATP used in the present study was not enterically coated
and was fed encapsulated as the disodium salt. The
sodium salt would have provided buffering of the ATP
through the stomach and the ATP itself should have
been metabolically available as soon as it reached the
proximal duodenum, which has been shown to be the
most biologically active site for ATP metabolism and/or
absorption [17]. In France, this chemical form of ATP is
approved as a drug for lower back pain [27,28]. One
proposed mechanism of action is through improved oxy-
genation of the muscle, which could be of similar benefit
during exhaustive exercise.
Figure 2 High Peak Torque (A); Low Peak Torque (B) and Torque Fatigue (C) over 3 successive sets of 50-contraction knee extensions
in Placebo - - ♦- - and 400 mg ATP/d —▪— supplemented participants. Treatment with ATP approached an overall treatment main effect over
placebo supplementation for Low Peak Torque and Torque Fatigue (B and C, † p < 0.11). ATP supplementation resulted in a significant improvement in
Set 2 Low Peak Torque (B, * p < 0.01) and a trend for less Torque Fatigue in Set 3 (C, # p < 0.10).
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indirectly impact work performance as ATP has immu-
nomodulatory effects [29], and inotropic effects on car-
diac muscle [30,31]. Oral administration of ATP to
rabbits for 14 days results in systemic effects through a
reduction in peripheral vascular resistance, improvement
of cardiac output, reduction of lung resistance, and
increased arterial PaO2 [32]. A study in humans demon-
strated that interstitial infusion of adenosine in muscle
induced nitric oxide formation in skeletal muscle and
nitric oxide and prostacyclin formation in microvascularendothelial cells [15]. Alternatively, the effects of cbvex-
ogenously administered ATP may also be due to the
associated increase in plasma uric acid, which has been
proposed to act as an anti-oxidant [33,34]. Increased
plasma uric acid has been demonstrated with ATP sup-
plementation [17,18]. These studies may indicate further
metabolism of adenosine before becoming bioavailable
and warrant further investigation. These effects of ATP
and adenosine could account, at least in part, for the
improvements in low peak torque and torque fatigue we
observed. The current study tested the hypothesis that
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sity exercise. While we have shown this may be possible,
the current study did not utilize methodologies to inves-
tigate the potential mechanism for the effects we
observed. Further studies should incorporate measures
of ATP and metabolites in blood components, should
include measures of blood oxygenation and muscle
blood flow, and also should investigate the extracellular
role of ATP on the neuromuscular junction via Ca2+
mediated effects [35] as indicators of the potential
mechanism by which oral ATP affects the ability to per-
form strenuous exercise.
Our study, like others in the literature, has limitations.
The number of participants in the present study (n=16),
while higher than that (n=9) previously studied by Jordan
et al. [21], may not be sufficient to answer all the questions
needed to validate the findings. Another limitation may
relate to the timing of the last dose of oral ATP (or pla-
cebo) given. In our study the last dose was consumed 12
hours prior to testing. This contrasts with the study by
Jordan et al. who studied participants after 14 days of sup-
plementation and 3 hours post supplement dosing, and
found ATP increased within group set 1 repetitions and
total lifting volume [21]. Another potential limitation is
that the study involved eumenorrheic females who were
not differentiated based upon phase of the menstrual
cycle. Other potential limitations include participants’
potential variation in physical activity or diet before test-
ing. However, participants did commit to maintaining
their physical activity level for the duration of the study
and to exercise restrictions for 3 days prior to testing
which within a crossover design should have minimized
the effect of activity on the results. Additionally, partici-
pants were required to repeat a similar dietary intake 24 h
before each testing period and the testing was performed
after an overnight fast which should have minimized any
acute dietary effect on testing results.Conclusions
In conclusion, the current study demonstrated that sup-
plementation with 400 mg ATP/d for 15 days tended to
reduce muscle fatigue while improving muscle low peak
torque through successive sets of exhaustive exercise.
These effects may indicate an improvement in overall
training stimulus which may have been brought about
by more rapid repolarization and stronger action poten-
tials later within sets, which should be investigated
further.Additional file
Additional file 1: Table S1. Blood chemistry values before and after 15
days of supplementation with either a placebo or 400 mg ATP/d.* TableS2. Blood hematology values before and after 15 days of
supplementation with either a placebo or 400 mg ATP/d.*
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